In contrast to beneficial effects in IBD, SR3335 inhibited TNFα in TH17 and TH17.1 cells; inhibition of TNF signaling, via use of non-selective TNF inhibitors, exacerbated MS62,63 and induced new cases of demyelinating disease and neuropathies in patients treated for other inflammatory diseases64,65. This evidence concerns the gene TNF and demyelinating disease.